Navigation Links
Pfizer Whistleblower Named Year's Most Influential Person In Business Ethics
Date:12/18/2009

WASHINGTON, Dec. 18 /PRNewswire-USNewswire/ -- John Kopchinski, the whistleblower whom Phillips & Cohen LLP represented in a successful, record-setting "qui tam" case against Pfizer Inc., has been named as the most influential person in business ethics for 2009.

Ethisphere, a think tank that focuses on business ethics, corporate social responsibility, anti-corruption and sustainability, compiles an annual list of the 100 most influential people in business ethics. The group named Kopchinski number one on its 2009 list.

A former sales representative for Pfizer, Kopchinski exposed the company's illegal sales and marketing campaign for the prescription painkiller Bextra for uses and in doses that endangered patients' health and lives. (See http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements531.asp)

Pfizer paid $1.8 billion in September to the government to settle Kopchinski's qui tam lawsuit and a related criminal charge. The company settled four other whistleblower lawsuits at the same time, bringing the total settlement to $2.3 billion. It was the largest healthcare fraud settlement ever and the largest criminal fine ever imposed in the U.S.

"John Kopchinski wasn't seen as a team player and ultimately lost his job at Pfizer," said Erika Kelton, a Washington, DC, attorney with Phillips & Cohen. "But the happy ending to his story and the recognition this honor bestows should give other whistleblowers hope."

Kopchinski "officially turned whistleblowing into big business," said Ethisphere. He received more than $70 million as a reward for the work he and his attorneys did on the Pfizer case. The False Claims Act requires the government to award whistleblowers a percentage of the funds the government recovers as a result of their qui tam cases.

Phillips & Cohen specializes in representing whistleblowers in cases involving fraud against the government, tax matters and securities violations. Cases brought by the firm's attorneys have recovered more than $5.3 billion in civil and criminal penalties for the government. For more information about whistleblowers and qui tam cases, see www.phillipsandcohen.com.

For more information about the Pfizer qui tam case and settlement, see http://www.phillipsandcohen.com/CM/NewsSettlements/NewsSettlements536.asp

SOURCE Phillips & Cohen LLP


'/>"/>
SOURCE Phillips & Cohen LLP
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... (NYSE: DVA ) today announced results for the ... Net income attributable to DaVita Inc. for the quarter and ... per share and $880 million, or $4.29 per share, respectively. ... for the quarter and year ended December 31, 2016, excluding ... per share, and $789 million, or $3.85 per share, respectively. ...
(Date:2/16/2017)... ST. LOUIS , Feb. 16, 2017  Express Scripts (NASDAQ: ... one of the World,s Most Admired Companies within the Health Care: ... to be named one of the World,s Most Admired Companies," said ... is driven by the commitment and passion of our 26,000 employees ... people we serve." ...
(Date:2/16/2017)... Research and Markets has announced the addition of the "Global ... Cancer Type, Technology - Forecast to 2025" report to their ... The ... a CAGR of around 28.6% over the next decade to reach ... the prominent trends that the market is witnessing include increasing demand ...
Breaking Medicine Technology:
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... today provides the latest information and contact points to easily connect elderly veterans ... care, assisted living, and elder-care funding. It also conveys material on this year's ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... for the electronic prescribing of controlled and non-controlled substances plus the ability to ... pharmacies in the United States now accept electronic prescriptions, according to the Office ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... February 17, 2017 ... ... Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? ...
(Date:2/17/2017)... Austin, Tx (PRWEB) , ... February 17, 2017 ... ... of revenue cycle management services, announced today that Karen Pilley has been promoted ... expenses is critical in today’s shifting healthcare paradigm – a shift that demands ...
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the nation, Onslow ... part by the Hospital Readmission Reduction Program (HRRP), the return of a patient to ... hospitals across the nation. While many providers are struggling to leverage limited resources and ...
Breaking Medicine News(10 mins):